Economic evaluation of biosimilars for reimbursement purposes – what, when, how?

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?

Background: Limited previous research and guidelines on the design of economic evaluation for biosimilars have led to unresolved methodological questions on how to assess biosimilars. Objectives: We want to raise awareness of and explore methodological issues for the economic evaluation of biosimila...

Full description

Bibliographic Details
Main Authors:	Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G. Vulto, Steven Simoens
Format:	Article
Language:	English
Published:	MDPI AG 2020-01-01
Series:	Journal of Market Access & Health Policy
Subjects:	biosimilars economic evaluation reimbursement cost-minimization comparator indication off-patent biologicals
Online Access:	http://dx.doi.org/10.1080/20016689.2020.1739509

Similar Items

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
by: Teresa Barcina Lacosta, et al.
Published: (2023-01-01)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
by: Evelien Moorkens, et al.
Published: (2020-01-01)

Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
by: Liese Barbier, et al.
Published: (2021-05-01)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022-12-01)

Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access
by: Olga Barszczewska, et al.
Published: (2020-06-01)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
by: Yannick Vandenplas, et al.
Published: (2021-02-01)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
by: Yannick Vandenplas, et al.
Published: (2022-01-01)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
by: Liese Barbier, et al.
Published: (2022-07-01)

Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
by: Liese Barbier, et al.
Published: (2022-03-01)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2021-01-01)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
by: Elif Car, et al.
Published: (2023-04-01)

The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
by: Yannick Vandenplas, et al.
Published: (2023-07-01)

Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
by: Liese Barbier, et al.
Published: (2021-12-01)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
by: Tim A. Kanters, et al.
Published: (2017-05-01)

Biosimilars for Haematologic Malignancies: The Path to Sustainable Care
by: Paul Cornes, et al.
Published: (2017-08-01)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
by: Hajer Dahmani, et al.
Published: (2023-12-01)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021-05-01)

Regulatory considerations for biosimilars
by: Ranjani Nellore
Published: (2010-01-01)

Tendering and biosimilars: what role for value-added services?
by: Steven Simoens, et al.
Published: (2020-01-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
by: Alessandra Blonda, et al.
Published: (2022-07-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

An international comparative analysis and roadmap to sustainable biosimilar markets
by: Khalid A. Alnaqbi, et al.
Published: (2023-08-01)

Biosimilar monoclonal antibodies in China: A patent review
by: Jia-Wei Liu, et al.
Published: (2022-06-01)

Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
by: Yannick Vandenplas, et al.
Published: (2022-09-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
by: Yujeong Kim, et al.
Published: (2020-07-01)

From generic to biosimilar drugs: why take an innovative pace?
by: Fereshteh Barei, et al.
Published: (2012-12-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness
by: Claudio Jommi, et al.
Published: (2022-09-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Biosimilars: development and investigation using achievements in modern biotechnology
by: R. R. Niyazov, et al.
Published: (2021-02-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)